CD155 expression and its prognostic value in postoperative patients with breast cancer

Yong, Hongmei; Cheng, Ronghui; Li, Xia; Gao, Guangyi; Jiang, Xuan; Cheng, Hongyun; Zhou, Xueyi; Zhao, Wei

doi:10.1016/j.biopha.2019.108884

Cited by 40 publications

(43 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 In two recently published studies, the authors analyzed the PVR protein expression by immunohistochemistry in large cohorts of breast cancer patients. In both studies, high PVR expression was associated with poor patients' outcome 41,42 supporting our findings. Moreover, these observations are in line with the correlation between PVR mRNA and protein levels that we found in our patient cohort.…”

Section: Discussionsupporting

confidence: 88%

Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer

et al. 2019

View full text Add to dashboard Cite

Immune checkpoints are intensively investigated as targets in cancer therapy. T-cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT) and its ligand poliovirus receptor (PVR) are recently emerging as novel promising targets in immunotherapy. Here, we show that high expression of PVR represents an independent prognostic marker being associated with poor outcome for breast cancer patients. Furthermore, PVR mRNA, as well as protein expression, is associated with more aggressive breast cancer subtypes such as HER2 positive and triple-negative breast cancer. In vitro, blocking TIGIT or PVR resulted in enhanced immune cell-mediated lysis of breast cancer cell lines SKBR-3, MDA-MB-231, MDA-MB-468, and BT549 and additionally increased the cytotoxic effects of a bispecific T cell engager BiTE® antibody construct targeting EGFR. Taken together, our data identify the immune checkpoint factor PVR as a novel prognostic marker in breast cancer and indicate that blocking the TIGIT-PVR axis might represent a novel therapeutic option for the treatment of breast cancer patients.

show abstract

Section: Discussionsupporting

confidence: 88%

Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The prognostic effect of CD155 expression on BC was confirmed in another two publications [25,26]. The two articles presented a significant association between CD155 expression with NK [25] and cytotoxic and macrophage-TILs [26]; however, we not only observed a significant relationship with TILs but also a significant relationship with PD-1 + TILs (dysfunctional TILs). Therefore, we concluded the exhausted TILs, but not the functional TILs related with CD155.…”

Section: Discussionsupporting

confidence: 69%

“…Intratumoral treatment of the recombinant nonpathogenic polio-rhinovirus chimera to patients with recurrent glioblastoma prolonged the survival length, comparing with the historical controls [24]. The prognostic effect of CD155 expression on BC was confirmed in another two publications [25,26]. The two articles presented a significant association between CD155 expression with NK [25] and cytotoxic and macrophage-TILs [26]; however, we not only observed a significant relationship with TILs but also a significant relationship with PD-1 + TILs (dysfunctional TILs).…”

Section: Discussionmentioning

confidence: 83%

Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study

Zhou

Song

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Purpose. The immune checkpoint inhibitor is approved for breast cancer treatment, but the low expression of PD-L1 limits the immunotherapy. CD155 is another immune checkpoint protein in cancers and interacts with ligands to regulate immune microenvironment. This study is aimed at investigating the expression of CD155 and the association with prognosis and pathological features of breast cancer. Methods. 126 patients were recruited this cohort study consecutively, and CD155 expression on tumor cells was detected by immunohistochemistry. The Kaplan-Meier survival curve and Cox hazard regression model were used to estimate the association. Results. 38.1% patients had an overexpression of CD155, and the proportion of tumor cells with CD155 overexpression was 17%, 39%, 37%, and 62% among Luminal A, Luminal B, HER2-positive, and triple negative breast cancer cases, respectively (p<0.05). Patients with CD155 overexpression had the Ki-67 index significantly higher than that of patients with low expression (42% vs. 26%). Though the number of tumor-infiltrating lymphocytes was higher among patients with CD155 overexpression (144/HPF vs. 95/HPF), the number of PD-1+ lymphocytes was significantly higher (52/HPF vs. 25/HPF, p<0.05). Patients of CD155 overexpression had the disease-free and overall survival decreased by 13 months and 9 months, respectively (p<0.05). CD155 overexpression was associated with an increased relapse (HR=13.93, 95% CI 2.82, 68.91) and death risk for breast cancer patients (HR=5.47,1.42,20.99). Conclusions. Overexpression of CD155 was correlated with more proliferative cancer cells and a dysfunctional immune microenvironment. CD155 overexpression introduced a worse relapse-free and overall survival and might be a potential immunotherapy target for breast cancer.

show abstract

“…Elevated CD155 expression has been reported in melanoma (Bevelacqua et al 2012), many other solid cancers (Carlsten et al 2009, Gromeier et al 2000, Masson et al 2001, Nakai et al 2010, Nishiwada et al 2015, and blood cancers (Pende et al 2005). High expression has been associated with poor clinical measures including tumor histological grade, primary tumor size, lymph node metastasis, reduction in tumor-infiltrating lymphocytes, and poor prognosis in retrospective studies across various solid cancer types (Huang et al 2017, Nishiwada et al 2015, Yong et al 2019. To better understand the relationship between CD155 and clinical correlates, researchers are conducting several clinical trials that are attempting to measure CD155 expression in tumor tissue prior to, or following, the initiation of various treatments in several cancers (https://clinicaltrials.gov identifiers NCT03667716, NCT03712358, NCT03789682, NCT03342417, NCT03071328).…”

Section: Cd155mentioning

confidence: 99%

Cancer Immunotherapy and the Nectin Family

Johnston

Lee

Strop

et al. 2021

Annu. Rev. Cancer Biol.

View full text Add to dashboard Cite

It is increasingly clear that the nectin family and its immunoreceptors shape the immune response to cancer through several pathways. Yet, even as antibodies against TIGIT, CD96, and CD112R advance into clinical development, biological and therapeutic questions remain unanswered. Here, we review recent progress, prospects, and challenges to understanding and tapping this family in cancer immunotherapy. Expected final online publication date for the Annual Review of Cancer Biology, Volume 5 is March 4, 2021. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

show abstract

CD155 expression and its prognostic value in postoperative patients with breast cancer

Cited by 40 publications

References 27 publications

Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer

Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer

Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study

Cancer Immunotherapy and the Nectin Family

Contact Info

Product

Resources

About